AR024145A1 - Derivados de 5-fenil-pirimidina - Google Patents
Derivados de 5-fenil-pirimidinaInfo
- Publication number
- AR024145A1 AR024145A1 ARP000102642A ARP000102642A AR024145A1 AR 024145 A1 AR024145 A1 AR 024145A1 AR P000102642 A ARP000102642 A AR P000102642A AR P000102642 A ARP000102642 A AR P000102642A AR 024145 A1 AR024145 A1 AR 024145A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- hydrogen
- halogen
- receptor
- compounds
- Prior art date
Links
- LVXOXXGCJHYEOS-UHFFFAOYSA-N 5-phenylpyrimidine Chemical class C1=CC=CC=C1C1=CN=CN=C1 LVXOXXGCJHYEOS-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052736 halogen Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- -1 lower alkoxyloxy Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Compuestos de formula general (1) en donde: R1 es hidrogeno o halogeno; R2 es hidrogeno, halogeno, alquilo inferior o alcoxilo inferior; R3 es halogeno,trifluorometilo, alcoxilo inferior o alquilo inferior; R4 y R4 son independientemente entre sí, hidrogeno o alquilo inferior; R5 es alquilo inferior, alcoxiloinferior, amino, hidroxilo, hidroxialquilo inferior, -(CH2)n-piperazinilo, -(CH2)n-morfolinilo opcionalmente substituido con alquilo inferior,-(CH2)n+1-imidazolilo, -O-(CH2)n+1-morfolinilo,-O-(CH2)n+1-piperidinilo, alquilo inferior-sulfanilo, alquilo inferior-sulfonilo, bencilamino,-NH-(CH2)n+1N(R4)2, -(CH2)n-NH-(CH2)n+1N(R4)2, -(CH2)n+1N(R4)2, o -O-(CH2)n+1N(R4)2, en donde R4 es hidrogeno o alquilo inferior; R6 es hidrogeno; R2y R6 oR1 y R6 pueden ser juntamente con los dos átomos de C del anillo, -CH=CH-CH=CH-, con la condicion de que n para R1 sea 1; n es independientemente 0-2; yX es -C(O)N(R4)- o N(R4)C(O)-; y las sales de adicion ácida farmacéuticamente aceptables de los mismos. Los compuestos de formula (1) tienen una elevadaafinidad para el receptor de la NK-1. Son por lo tanto, de utilidad para el tratamiento de enfermedades que están relacionadas con este receptor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99110482 | 1999-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024145A1 true AR024145A1 (es) | 2002-09-04 |
Family
ID=8238270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000102642A AR024145A1 (es) | 1999-05-31 | 2000-05-29 | Derivados de 5-fenil-pirimidina |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US6756380B1 (es) |
| EP (1) | EP1187814B1 (es) |
| JP (1) | JP3590591B2 (es) |
| KR (1) | KR100478369B1 (es) |
| CN (1) | CN1187338C (es) |
| AR (1) | AR024145A1 (es) |
| AT (1) | ATE273962T1 (es) |
| AU (1) | AU769265B2 (es) |
| BR (1) | BR0011097A (es) |
| CA (1) | CA2375670C (es) |
| CO (1) | CO5170529A1 (es) |
| CZ (1) | CZ20014273A3 (es) |
| DE (1) | DE60013127T2 (es) |
| DK (1) | DK1187814T3 (es) |
| ES (1) | ES2225144T3 (es) |
| GC (1) | GC0000338A (es) |
| HK (1) | HK1046411B (es) |
| HR (1) | HRP20010867A2 (es) |
| HU (1) | HU225016B1 (es) |
| IL (2) | IL146519A0 (es) |
| JO (1) | JO2308B1 (es) |
| MA (1) | MA26794A1 (es) |
| MX (1) | MXPA01011704A (es) |
| MY (1) | MY136258A (es) |
| NO (1) | NO321334B1 (es) |
| NZ (1) | NZ515408A (es) |
| PE (1) | PE20010203A1 (es) |
| PL (1) | PL353492A1 (es) |
| PT (1) | PT1187814E (es) |
| RU (1) | RU2244710C2 (es) |
| SI (1) | SI1187814T1 (es) |
| TR (1) | TR200103460T2 (es) |
| TW (1) | TWI263638B (es) |
| WO (1) | WO2000073278A2 (es) |
| YU (1) | YU85001A (es) |
| ZA (1) | ZA200109496B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
| PL362551A1 (en) * | 2000-06-13 | 2004-11-02 | Basf Aktiengesellschaft | Fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines |
| JP4092203B2 (ja) | 2000-12-21 | 2008-05-28 | ニトロメッド，インク． | 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法 |
| CA2490148A1 (en) | 2002-07-02 | 2004-01-15 | F. Hoffmann-La Roche Ag | 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix |
| TWI359017B (en) * | 2003-11-10 | 2012-03-01 | Synta Pharmaceuticals Corp | Heteroaryl-hydrazone compounds |
| JP2007217282A (ja) * | 2004-03-04 | 2007-08-30 | Astellas Pharma Inc | 置換ピリミジン誘導体 |
| PL1747204T3 (pl) * | 2004-04-22 | 2009-01-30 | Procter & Gamble | Tripodstawione moczniki jako inhibitory cytokin |
| TW200628159A (en) * | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| CN101128189A (zh) | 2005-02-25 | 2008-02-20 | 弗·哈夫曼-拉罗切有限公司 | 药物物质分散性改善的片剂 |
| US9013997B2 (en) * | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| US10000459B2 (en) | 2013-03-15 | 2018-06-19 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| GB201316600D0 (en) * | 2013-09-18 | 2013-10-30 | Redx Pharma Ltd | Agricultural chemicals |
| WO2016021562A1 (ja) * | 2014-08-06 | 2016-02-11 | キッセイ薬品工業株式会社 | シアノチオフェン誘導体 |
| EA038960B1 (ru) | 2015-01-30 | 2021-11-15 | Басф Се | Гербицидные фенилпиримидины |
| BR112018076700A2 (pt) | 2016-07-20 | 2019-04-02 | Basf Se | composições herbicida e seu uso e método de controle da vegetação indesejada |
| CN109476630A (zh) * | 2016-07-25 | 2019-03-15 | 巴斯夫欧洲公司 | 除草的嘧啶化合物 |
| EA201990335A1 (ru) | 2016-07-25 | 2019-07-31 | Басф Се | Гербицидные пиримидиновые соединения |
| AU2017302983A1 (en) | 2016-07-26 | 2019-01-03 | Basf Se | Herbicidal pyrimidine compounds |
| BR112018077223A2 (pt) | 2016-07-27 | 2019-04-09 | Basf Se | compostos de pirimidina, uso de compostos de pirimidina, composições herbicidas, método para controlar vegetação indesejada e uso das composições herbicidas |
| WO2018019574A1 (en) | 2016-07-28 | 2018-02-01 | Basf Se | Herbicidal pyrimidine compounds |
| CA3064513A1 (en) | 2017-06-14 | 2018-12-20 | Basf Se | Herbicidal pyrimidine compounds |
| WO2019121352A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
| WO2019121374A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
| WO2019121373A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
| WO2019121408A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
| PL3853219T3 (pl) * | 2018-09-19 | 2023-12-18 | Bayer Aktiengesellschaft | Herbicydowo działające podstawione fenylopirymidynohydrazydy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940394A (en) * | 1972-03-31 | 1976-02-24 | Santilli Arthur A | 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides |
| AR208171A1 (es) | 1972-09-29 | 1976-12-09 | Ciba Geigy Ag | Procedimiento para la obtencion de nuevos derivados del acido cef-3-em-4-carboxilico |
| DE69428913T2 (de) | 1993-12-29 | 2002-05-29 | Merck Sharp & Dohme Ltd., Hoddesdon | Substituierte morpholinderivate und ihre verwendung als arzneimittel |
| WO1997009315A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
-
2000
- 2000-01-02 JO JO200082A patent/JO2308B1/en active
- 2000-05-19 TW TW089109624A patent/TWI263638B/zh not_active IP Right Cessation
- 2000-05-22 US US09/575,789 patent/US6756380B1/en not_active Expired - Fee Related
- 2000-05-24 HR HR20010867A patent/HRP20010867A2/hr not_active Application Discontinuation
- 2000-05-24 RU RU2001133456/04A patent/RU2244710C2/ru not_active IP Right Cessation
- 2000-05-24 TR TR2001/03460T patent/TR200103460T2/xx unknown
- 2000-05-24 IL IL14651900A patent/IL146519A0/xx not_active IP Right Cessation
- 2000-05-24 DK DK00935104T patent/DK1187814T3/da active
- 2000-05-24 HK HK02108020.5A patent/HK1046411B/zh not_active IP Right Cessation
- 2000-05-24 ES ES00935104T patent/ES2225144T3/es not_active Expired - Lifetime
- 2000-05-24 CN CNB008082847A patent/CN1187338C/zh not_active Expired - Fee Related
- 2000-05-24 JP JP2000621344A patent/JP3590591B2/ja not_active Expired - Fee Related
- 2000-05-24 MX MXPA01011704A patent/MXPA01011704A/es active IP Right Grant
- 2000-05-24 AT AT00935104T patent/ATE273962T1/de not_active IP Right Cessation
- 2000-05-24 PT PT00935104T patent/PT1187814E/pt unknown
- 2000-05-24 AU AU50708/00A patent/AU769265B2/en not_active Ceased
- 2000-05-24 YU YU85001A patent/YU85001A/sh unknown
- 2000-05-24 WO PCT/EP2000/004702 patent/WO2000073278A2/en not_active Ceased
- 2000-05-24 EP EP00935104A patent/EP1187814B1/en not_active Expired - Lifetime
- 2000-05-24 HU HU0201527A patent/HU225016B1/hu not_active IP Right Cessation
- 2000-05-24 SI SI200030472T patent/SI1187814T1/xx unknown
- 2000-05-24 PL PL00353492A patent/PL353492A1/xx unknown
- 2000-05-24 KR KR10-2001-7015319A patent/KR100478369B1/ko not_active Expired - Fee Related
- 2000-05-24 CA CA002375670A patent/CA2375670C/en not_active Expired - Fee Related
- 2000-05-24 CZ CZ20014273A patent/CZ20014273A3/cs unknown
- 2000-05-24 BR BR0011097-3A patent/BR0011097A/pt not_active Application Discontinuation
- 2000-05-24 DE DE60013127T patent/DE60013127T2/de not_active Expired - Fee Related
- 2000-05-24 NZ NZ515408A patent/NZ515408A/xx unknown
- 2000-05-26 PE PE2000000509A patent/PE20010203A1/es not_active Application Discontinuation
- 2000-05-29 MY MYPI20002385A patent/MY136258A/en unknown
- 2000-05-29 CO CO00039601A patent/CO5170529A1/es not_active Application Discontinuation
- 2000-05-29 AR ARP000102642A patent/AR024145A1/es not_active Application Discontinuation
- 2000-05-30 GC GCP2000685 patent/GC0000338A/en active
-
2001
- 2001-11-15 IL IL146519A patent/IL146519A/en unknown
- 2001-11-16 ZA ZA200109496A patent/ZA200109496B/en unknown
- 2001-11-22 NO NO20015701A patent/NO321334B1/no not_active Application Discontinuation
- 2001-11-26 MA MA26425A patent/MA26794A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024145A1 (es) | Derivados de 5-fenil-pirimidina | |
| PE20040937A1 (es) | Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4) | |
| HUP0402336A2 (hu) | Tieno[2,3-d]pirimidin-2,4-dion-származékok, eljárás előállításukra, alkalmazásuk autoimmun betegségek modulálására és a vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP0301120A2 (hu) | Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| UA74391C2 (uk) | Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти | |
| YU59602A (sh) | Aril fuzionisana azapoliciklična jedinjenja | |
| AR006360A1 (es) | Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion. | |
| DK0677046T3 (da) | Piperazinderivater som 5-HT-antagonister. | |
| ES2108717T3 (es) | Derivados de la tetrahidropirrolo(1,2-a)pirazina-4-espiro-3'-pirrolidina, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| JO2321B1 (en) | 4-phenyl-pyridine derivatives | |
| ES8200011A1 (es) | Procedimiento de preparacion de una composicion farmaceuticaen particular psicotropa. | |
| EA199801028A1 (ru) | Применение производных п-аминофенола для проготовления фармацевтических композиций, используемых при лечении нейродегенеративных заболеваний | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
| AR024146A1 (es) | Derivados de 4-fenil-pirimidina | |
| ATE59632T1 (de) | Dihydrodibenzocycloheptylidenethylamin-derivate | |
| YU47694B (sh) | Novi derivati 1,8-benzonaftiridina, postupak za njihovo dobivanje i postupak za dobivanje farmaceutske smeše | |
| TW324009B (en) | Pyrazole condensation ring derivative, its production process and its use as androgen inhibitor | |
| ES2083972T3 (es) | Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras. | |
| CO5160261A1 (es) | Derivados de bifenilo sustituidos que son antagonistas nk-1, su procedimiento de sintesis y composiciones farmaceuticas que los contienen | |
| DE69330601D1 (de) | Serotoninergische ergolin derivate | |
| TR200002831A2 (tr) | Kinolin-4-İl türevleri I | |
| TR200200969T2 (tr) | Karbonilamino türevlerinin CNS bozukluklarına karşı kullanılması | |
| NO973342L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av cerebrale degenerative sykdommer | |
| NO973340L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av fedme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |